TWI906448B - Kras g12c抑制劑在治療癌症中之用途 - Google Patents

Kras g12c抑制劑在治療癌症中之用途

Info

Publication number
TWI906448B
TWI906448B TW111100657A TW111100657A TWI906448B TW I906448 B TWI906448 B TW I906448B TW 111100657 A TW111100657 A TW 111100657A TW 111100657 A TW111100657 A TW 111100657A TW I906448 B TWI906448 B TW I906448B
Authority
TW
Taiwan
Prior art keywords
subject
kras
mutation
formula
stk11
Prior art date
Application number
TW111100657A
Other languages
English (en)
Chinese (zh)
Other versions
TW202241442A (zh
Inventor
安吉斯 李 央
哈比 海納瑞
格塔力 葛恰納瑞
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202241442A publication Critical patent/TW202241442A/zh
Application granted granted Critical
Publication of TWI906448B publication Critical patent/TWI906448B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW111100657A 2021-01-08 2022-01-07 Kras g12c抑制劑在治療癌症中之用途 TWI906448B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163135449P 2021-01-08 2021-01-08
US63/135,449 2021-01-08
US202163189625P 2021-05-17 2021-05-17
US63/189,625 2021-05-17

Publications (2)

Publication Number Publication Date
TW202241442A TW202241442A (zh) 2022-11-01
TWI906448B true TWI906448B (zh) 2025-12-01

Family

ID=80222156

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111100657A TWI906448B (zh) 2021-01-08 2022-01-07 Kras g12c抑制劑在治療癌症中之用途

Country Status (8)

Country Link
US (1) US20240091230A1 (https=)
EP (2) EP4650006A3 (https=)
JP (1) JP2024502446A (https=)
AU (1) AU2022205969A1 (https=)
CA (1) CA3206523A1 (https=)
MX (1) MX2023007918A (https=)
TW (1) TWI906448B (https=)
WO (1) WO2022150628A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
EP3738593A1 (en) * 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 HONG DAVID S. ET AL KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors THE NEW ENGLAND JOURNAL OF MEDICINE vol. 383, no. 13 2020/09/24 1207-1217

Also Published As

Publication number Publication date
EP4650006A3 (en) 2026-01-14
US20240091230A1 (en) 2024-03-21
AU2022205969A1 (en) 2023-07-06
EP4650006A2 (en) 2025-11-19
TW202241442A (zh) 2022-11-01
WO2022150628A1 (en) 2022-07-14
EP4274579A1 (en) 2023-11-15
MX2023007918A (es) 2023-07-13
CA3206523A1 (en) 2022-07-14
AU2022205969A9 (en) 2024-02-08
JP2024502446A (ja) 2024-01-19

Similar Documents

Publication Publication Date Title
TWI906448B (zh) Kras g12c抑制劑在治療癌症中之用途
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
US20250375452A1 (en) Sotorasib dosing regimen
TW202302112A (zh) 索托拉西布給藥方案
CN105848678A (zh) 核酸生物标志物及其用途
US20260069593A1 (en) Methods for treating cancer
EP3908282B1 (en) Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
Johnson et al. 8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
WO2024015360A1 (en) Methods of treating cancer
HK40102675A (zh) 索托拉西布给药方案
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
HK40126893A (zh) 索托拉西布/卡铂/培美曲塞在癌症治疗中的剂量方案
EA051386B1 (ru) Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c
HK40111140A (zh) 用於治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
CN116981462A (zh) 索托拉西布给药方案
KR20250170664A (ko) 암 치료에서 소토라십/카보플라틴/페메트렉시드에 대한 투여량 양생법
Langer Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.